Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darvadstrocel repeat administration in Crohn's disease with complex perianal fistula
NCT04118088Phase 4Terminated
- Sponsor
- Takeda
- Start
- Dec 2020
- Primary completion
- Feb 2025
- Modality
- Stem Cell Therapies
- Countries
- 6
01
Overview
Phase 4, open-label, single-arm trial of darvadstrocel in perianal fistula, sponsored by Takeda. Primary endpoints: Treatment-Emergent Adverse Event at 156 weeks, Treatment Emergent Serious Adverse Event at 156 weeks and 2 more. Started Dec 2020; status: terminated.
02
Drugs
darvadstrocel
03
Conditions
perianal fistula
Beyond the preview
Go deeper on NCT04118088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04118088.